四川精神卫生
四川精神衛生
사천정신위생
SICHUAN MENTAL HEALTH
2015年
4期
314-316
,共3页
齐拉西酮注射液%氟哌啶醇注射液%儿童精神分裂症%急性激越症状
齊拉西酮註射液%氟哌啶醇註射液%兒童精神分裂癥%急性激越癥狀
제랍서동주사액%불고정순주사액%인동정신분렬증%급성격월증상
Ziprasidone injection%Haloperidol injection%Childhood schizophrenia%Acute agitation symptoms
目的：探讨齐拉西酮注射液治疗儿童精神分裂症患者急性激越症状的临床效果及安全性。方法采用随机数字表法将符合《国际疾病分类（第10版）》（ICD -10）精神分裂症诊断标准的有急性激越症状的70例儿童患者分为实验组和对照组各35例，实验组给予齐拉西酮注射液，对照组给予氟哌啶醇注射液，疗程3天。于治疗前、治疗后2、12、24、48、72h 分别采用阳性和阴性症状量表（PANSS）减分率、临床疗效总评量表（CGI）评定疗效，治疗结束时采用副反应量表（TESS）评定安全性。结果疗程结束时实验组和对照组 PANSS 评分减分率分别为46.92％、49.46％，临床好转率分别为77.14％、80.00％，两组疗效比较差异均无统计学意义（P ＞0.05）；实验组和对照组不良反应发生率分别为20.00％、37.14％，差异有统计学意义（P ＜0.05）。结论齐拉西酮注射液对有急性激越症状的儿童精神分裂症患者的疗效与氟哌啶醇相当，不良反应发生率较低。
目的：探討齊拉西酮註射液治療兒童精神分裂癥患者急性激越癥狀的臨床效果及安全性。方法採用隨機數字錶法將符閤《國際疾病分類（第10版）》（ICD -10）精神分裂癥診斷標準的有急性激越癥狀的70例兒童患者分為實驗組和對照組各35例，實驗組給予齊拉西酮註射液，對照組給予氟哌啶醇註射液，療程3天。于治療前、治療後2、12、24、48、72h 分彆採用暘性和陰性癥狀量錶（PANSS）減分率、臨床療效總評量錶（CGI）評定療效，治療結束時採用副反應量錶（TESS）評定安全性。結果療程結束時實驗組和對照組 PANSS 評分減分率分彆為46.92％、49.46％，臨床好轉率分彆為77.14％、80.00％，兩組療效比較差異均無統計學意義（P ＞0.05）；實驗組和對照組不良反應髮生率分彆為20.00％、37.14％，差異有統計學意義（P ＜0.05）。結論齊拉西酮註射液對有急性激越癥狀的兒童精神分裂癥患者的療效與氟哌啶醇相噹，不良反應髮生率較低。
목적：탐토제랍서동주사액치료인동정신분렬증환자급성격월증상적림상효과급안전성。방법채용수궤수자표법장부합《국제질병분류（제10판）》（ICD -10）정신분렬증진단표준적유급성격월증상적70례인동환자분위실험조화대조조각35례，실험조급여제랍서동주사액，대조조급여불고정순주사액，료정3천。우치료전、치료후2、12、24、48、72h 분별채용양성화음성증상량표（PANSS）감분솔、림상료효총평량표（CGI）평정료효，치료결속시채용부반응량표（TESS）평정안전성。결과료정결속시실험조화대조조 PANSS 평분감분솔분별위46.92％、49.46％，림상호전솔분별위77.14％、80.00％，량조료효비교차이균무통계학의의（P ＞0.05）；실험조화대조조불량반응발생솔분별위20.00％、37.14％，차이유통계학의의（P ＜0.05）。결론제랍서동주사액대유급성격월증상적인동정신분렬증환자적료효여불고정순상당，불량반응발생솔교저。
Objective To investigate the clinical efficacy and safety of Ziprasidone injection on the therapy of acute agitation symptom of childhood schizophrenia. Methods 70 subjects with acute agitation symptoms conform to ICD - 10 for schizophrenia were randomly assigned into two groups,the research group(n = 35)were given ziprasidone injection,and the control group(n = 35)were given haloperidol injection for 3 days. Before and after treatment 2,12,24,48,72h of the respectively Positive and Negative Syn-drome Scale(PANSS)reduction rate,the end of the Clinical Global Impression Scale(CGI)were assessed. At the end of the treat-ment,the Treatment Emergent Symptom Scale(TESS)was assessed. Results At the end of the treatment,PANSS reduction rate was 46. 92% in the research group and the control group was 49. 46% ,the clinical improvement rate was 77. 14% in the research group and the control group was 80. 00% . No statistically significant differences between the two groups were found on efficacy(P > 0. 05). Adverse effects rate in the research group was 20. 00% ,the control group was 37. 14% ,there was significant difference between the two groups(P < 0. 05). Conclusion Ziprasidone injection is effective and haloperidol rather in treating the acute agitation symptoms of childhood schizophrenia,the rate of extrapyramidal adverse reaction was low.
